Plasma Gelatinase Levels in Patients with Primary Breast Cancer in Relation to Axillary Lymph Node Status, Her2/neu Expression and other Clinicopathological Variables

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical and Experimental Metastasis

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10585-005-3992-2PMID 16320112
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Matrix Metalloproteinase-2 (MMP-2) is Associated with the Risk for a Relapse in Postmenopausal Patients with Node-Positive Breast Carcinoma Treated with Antiestrogen Adjuvant Therapy

  2004cited by this paper
• Identification and validation of an ERBB2 gene expression signature in breast cancers

  2004cited by this paper
• Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis

  2004cited by this paper
• Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands

  2004cited by this paper
• Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera

  2004cited by this paper
• A High Serum Matrix Metalloproteinase-2 Level Is Associated with an Adverse Prognosis in Node-Positive Breast Carcinoma

  2004cited by this paper
• EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century.

  2003cited by this paper
• Metalloproteinases and their inhibitors in angiogenesis

  2003cited by this paper
• Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma

  2003cited by this paper
• Plasma MMP‐9 (92 kDa‐MMP) activity is useful in the follow‐up and in the assessment of prognosis in breast cancer patients

  2003cited by this paper
• Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma.

  2003cited by this paper
• New functions for the matrix metalloproteinases in cancer progression

  2002cited by this paper
• Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood.

  2001cited by this paper
• Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negativeatients

  2001cited by this paper
• Serum levels of matrix metalloproteinase 2 in patients with breast cancer.

  2001cited by this paper
• Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.

  2001cited by this paper
• Increased gelatinase‐A and gelatinase‐B activities in malignant vs. benign breast tumors

  2000cited by this paper
• Regulation of matrix metalloproteinase expression in tumor invasion

  1999cited by this paper
• Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues: Clinical and Experimental Applications

  1999cited by this paper
• MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma

  1999cited by this paper
• Matrix metalloproteinase‐2 immunoreactive protein

  1998cited by this paper
• Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model.

  1998cited by this paper
• Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.

  1997cited by this paper
• The Hemopexin-like Domain (C Domain) of Human Gelatinase A (Matrix Metalloproteinase-2) Requires Ca2+ for Fibronectin and Heparin Binding

  1997cited by this paper
• Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.

  1997cited by this paper
• Invasive phenotype of MCF10A cells overexpressing c‐Ha‐ras and c‐erbB‐2 oncogenes

  1995cited by this paper
• Growth factors in breast cancer.

  1995cited by this paper
• c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.

  1994cited by this paper
• M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer.

  1993cited by this paper
• Mr 92,000 Type IV Collagenase Is Increased in Plasma of Patients with Colon Cancer and Breast Cancer

  1993cited by this paper
• Prognostic factors and therapeutic decisions in axillary node-negative breast cancer.

  1992cited by this paper
• Prognostic factors and treatment decisions in axillary-node-negative breast cancer.

  1992cited by this paper
• The C-terminus of type I collagen is a major binding site for heparin.

  1986cited by this paper

• Linoleic acid promotes mammary tumor growth and metastasis to brain and lung in female Balb/cJ mice.

  2025cites this paper
• Quantification of MMP-2 and TIMP-1 expressions in breast cancer

  2023cites this paper
• Role of type 2 innate lymphoid cell and its related cytokines in tumor immunity

  2020cites this paper
• Collagenases and gelatinases and their inhibitors as anticancer agents

  2020cites this paper
• Prognostic significance of plasma matrix metalloprotease-2 in pancreatic cancer patients

  2017cites this paper
• The role of interleukin 8 and matrix metalloproteinases 2 and 9 in breast cancer treated with tamoxifen

  2017cites this paper
• Significance of Matrix Metalloproteinase 9 Expression as Supporting Marker to Cytokeratin 19 mRNA in Sentinel Lymph Nodes in Breast Cancer Patients

  2016cites this paper
• Neurotoxin-directed synthesis and in vitro evaluation of Au nanoclusters

  2015cites this paper
• A gallium telluride quantum dots bioelectrode system for human epidermal growth factor receptor-2 (Her2/neu) oncogene signalling

  2015cites this paper
• Immunoexpression of ROCK-1 and MMP-9 as prognostic markers in breast cancer.

  2014cites this paper
• The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer

  2012cites this paper
• Preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 ( MMP-9 ) are associated with prognosis of breast cancer

  2012cites this paper
• Results in treatment of early breast cancers and the level of selected metalloproteinases.

  2011cites this paper
• Quantum dots-based double-color imaging of HER2 positive breast cancer invasion.

  2011cites this paper
• COMPARISON OF SERUM AND PLASMA MMP-9 LEVEL IN BREAST CANCER PATIENTS

  2011cites this paper
• Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast.

  2011cites this paper
• Histamine and Breast Cancer: A New Role for a Well Known Amine

  2011cites this paper
• Serum MMP-9 Level Associated with Initiation and Progression Steps of Breast Cancer in the Iranian Population

  2010cites this paper
• Activity of MMP-2 and MMP-9 in sera of breast cancer patients.

  2010cites this paper
• Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer

  2009cites this paper
• Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review.

  2009cites this paper
• [Expression of MMP-9 and VEGF in breast cancer: correlation with other prognostic indicators].

  2008cites this paper
• Matrix Metalloproteinase Expression Patterns in Luminal A Type Breast Carcinomas

  2007cites this paper
• Plasma Matrix Metalloproteinase-9 Level Is Better than Serum Matrix Metalloproteinase-9 Level to Predict Gastric Cancer Evolution

  2007cites this paper
• The prognostic role of matrix metalloproteinases MMP-2 and -9 and their tissue inhibitors TIMP-1 and -2 in primary breast carcinoma

  2007cites this paper
• MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.

  2007cites this paper